John B. Harlow Jr. - 04 Dec 2025 Form 4 Insider Report for Esperion Therapeutics, Inc. (ESPR)

Reporting relationship: Chief Commercial Officer
Issuer ticker: ESPR
Reported as of: 04 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Dec 2025, 16:27:31 UTC
Prior SEC filing: 17 Nov 2025
Next SEC filing: 13 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Sheldon L. Koenig, by power of attorney

Filing notes and source

Key filing fact

John B. Harlow Jr. filed Form 4 for Esperion Therapeutics, Inc. (ESPR) on 08 Dec 2025.

Key facts

This page summarizes John B. Harlow Jr.'s Form 4 filing for Esperion Therapeutics, Inc. (ESPR).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 08 Dec 2025, 16:27.

Change

Previous filing in this sequence was filed on 17 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002095554 Primary reporting owner

Harlow John B. Jr.

Relationship: Chief Commercial Officer
Address: C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR
Signature: /s/ Sheldon L. Koenig, by power of attorney
Signature date: 08 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ESPR transaction

Common Stock

Award

Transaction value: $0
Shares: +424,536
Change %
Price: $0.000000
Shares after: 424,536
Date: 04 Dec 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ESPR transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +380,000
Change %
Price: $0.000000
Shares after: 380,000
Date: 04 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 380,000
Exercise price: $3.79
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Such award will vest over a four (4) year period as follows: 25% shall vest on the respective one year anniversary of the vesting commencement date of December 15, 2025 and the remainder shall vest in equal quarterly installments over the three (3) year period thereafter.